Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafenoquine Succinate

FDA-approved product (tablet, oral), marketed as Arakoda, Krintafel.

Registered studies
42
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafenoquine Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria
  • Plasmodium vivax malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafenoquine Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafenoquine Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

    NCT05947812 · start 2023-08-01

    Registered record
    Registry ID
    NCT05947812
    Conditions
    COVID 19 Disease; Mild to Moderate COVID 19 Disease; SARS-CoV-2; Infectious Disease; Severe Acute Respiratory Syndrome Coronavirus 2
    Interventions
    Tafenoquine Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-08-01
    Completion
    2024-04-27
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID 19 Disease; Mild to Moderate COVID 19 Disease; SARS-CoV-2; Infectious Disease +1 more
    InterventionTafenoquine Oral Tablet; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Tafenoquine and Primaquine in Colostrum and Breast Milk

    NCT04984759 · start 2023-07-01

    Registered record
    Registry ID
    NCT04984759
    Conditions
    Healthy Lactating Women
    Interventions
    Primaquine; Tafenoquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2023-07-01
    Completion
    2025-06-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Lactating Women
    InterventionPrimaquine; Tafenoquine
    PhasePhase 4
    Registry statusWithdrawn

  • ACT vs CQ With Tafenoquine for P. Vivax Mono-infection

    NCT05788094 · start 2023-06-26

    Registered record
    Registry ID
    NCT05788094
    Conditions
    Malaria; Malaria, Vivax; Plasmodium Vivax Malaria
    Interventions
    Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose); Chloroquine plus Tafenoquine (450 mg adult dose); Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-06-26
    Completion
    2026-08-31
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Malaria, Vivax; Plasmodium Vivax Malaria
    InterventionDihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose); Chloroquine plus Tafenoquine (450 mg adult dose); Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
    PhasePhase 4
    Registry statusRecruiting

  • Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield

    NCT05540470 · start 2022-09-12

    Registered record
    Registry ID
    NCT05540470
    Conditions
    Malaria, Vivax
    Interventions
    PART; Malakit; CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS; QUALITATIVE STUDY
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-12
    Completion
    2025-04-25
    Enrolment
    1,991

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionPART; Malakit; CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS; QUALITATIVE STUDY
    PhaseNot applicable
    Registry statusCompleted

  • Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

    NCT05753150 · start 2022-05-23

    Registered record
    Registry ID
    NCT05753150
    Conditions
    Malaria, Vivax; G6PD Deficiency
    Interventions
    Tafenoquine; Primaquine; Primaquine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-05-23
    Completion
    2023-10-01
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax; G6PD Deficiency
    InterventionTafenoquine; Primaquine; Primaquine
    PhaseNot recorded
    Registry statusCompleted

  • Escalating Monthly Doses of Tafenoquine in Healthy Volunteers

    NCT05203744 · start 2022-05-10

    Registered record
    Registry ID
    NCT05203744
    Conditions
    Prophylaxis
    Interventions
    Tafenoquine prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-05-10
    Completion
    2022-12-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProphylaxis
    InterventionTafenoquine prophylaxis
    PhasePhase 4
    Registry statusUnknown

  • Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

    NCT05081089 · start 2021-10-12

    Registered record
    Registry ID
    NCT05081089
    Conditions
    Malaria,Falciparum
    Interventions
    Artemether-lumefantrine; Primaquine Phosphate; Sulphadoxine-pyrimethamine with amodiaquine; Tafenoquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-10-12
    Completion
    2022-01-13
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionArtemether-lumefantrine; Primaquine Phosphate; Sulphadoxine-pyrimethamine with amodiaquine; Tafenoquine
    PhasePhase 2
    Registry statusCompleted

  • Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

    NCT05096702 · start 2021-09-09

    Registered record
    Registry ID
    NCT05096702
    Conditions
    Malaria, Vivax; G6PD Deficiency
    Interventions
    Tafenoquine; Primaquine; Primaquine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-09-09
    Completion
    2023-09-09
    Enrolment
    16,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax; G6PD Deficiency
    InterventionTafenoquine; Primaquine; Primaquine
    PhaseNot recorded
    Registry statusUnknown

  • Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

    NCT04411836 · start 2021-04-25

    Registered record
    Registry ID
    NCT04411836
    Conditions
    Vivax Malaria; Plasmodium Vivax; Malaria, Vivax; Malaria Relapse
    Interventions
    Tafenoquine; Primaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-04-25
    Completion
    2024-09-30
    Enrolment
    960

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVivax Malaria; Plasmodium Vivax; Malaria, Vivax; Malaria Relapse
    InterventionTafenoquine; Primaquine
    PhasePhase 3
    Registry statusCompleted

  • Tafenoquine in Patients With Mild to Moderate COVID-19

    NCT04533347 · start 2021-02-19

    Registered record
    Registry ID
    NCT04533347
    Conditions
    COVID 19 Disease
    Interventions
    Tafenoquine Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-02-19
    Completion
    2022-06-30
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID 19 Disease
    InterventionTafenoquine Oral Tablet; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

    NCT04609098 · start 2020-10-29

    Registered record
    Registry ID
    NCT04609098
    Conditions
    Malaria, Falciparum
    Interventions
    Dihydroartemisinin/Piperaquine; Tafenoquine 100mg [Arakoda]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-29
    Completion
    2020-12-23
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionDihydroartemisinin/Piperaquine; Tafenoquine 100mg [Arakoda]
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

    NCT02802501 · start 2018-04-08

    Registered record
    Registry ID
    NCT02802501
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine; Matched-Placebo for Tafenoquine; Primaquine; Matched-Placebo for Primaquine; Dihydroartemisinin-piperaquine (DHA-PQP); ACT plus PQ (Rescue medication); PQ (End of study treatment)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-08
    Completion
    2019-08-19
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine; Matched-Placebo for Tafenoquine; Primaquine; Matched-Placebo for Primaquine +3 more
    PhasePhase 3
    Registry statusCompleted

  • Long-Term Safety Study of Tafenoquine

    NCT03320174 · start 2017-10-05

    Registered record
    Registry ID
    NCT03320174
    Conditions
    Healthy Volunteers
    Interventions
    Tafenoquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-05
    Completion
    2021-07-13
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionTafenoquine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

    NCT02563496 · start 2017-02-06

    Registered record
    Registry ID
    NCT02563496
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine; Chloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-02-06
    Completion
    2020-02-17
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine; Chloroquine
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution

    NCT02751294 · start 2016-05

    Registered record
    Registry ID
    NCT02751294
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine Control; Tafenoquine dissolution profile X; Tafenoquine SIL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05
    Completion
    2016-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine Control; Tafenoquine dissolution profile X; Tafenoquine SIL
    PhasePhase 1
    Registry statusCompleted